ImmunityBio Logo
US45256X1037
A2QQ2E
IBRX

ImmunityBio

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 13,68 € (+129,92 %). La mediana es de 13,68 € (+129,92 %).

Comprar
  5
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • ImmunityBio stock rises after ANKTIVA approval in the UAE

    ImmunityBio shares climbed 7.5% after ANKTIVA was approved in the United Arab Emirates. The approval covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive, non‑muscle‑invasive bladder cancer and ANKTIVA 1.2 mg with immune checkpoint inhibitors for metastatic non‑small‑cell lung cancer. The approval expands ANKTIVA’s regulatory presence to 34 countries and is based on the QUILT‑3.032 study (in NMIBC: 71% complete response rate in the CIS cohort; 12‑month DFR 58.2% in papillary tumors; 83% cystectomy‑free at 36 months) and QUILT‑3.055 (in checkpoint‑refractory NSCLC: median overall survival 14.6 months). » Más en de.investing.com


  • ImmunityBio analysis: ANKTIVA plus BCG significantly more cost-effective than TAR-200 in bladder cancer

    A health economic analysis presented in Philadelphia shows that ANKTIVA combined with BCG achieves substantial cost savings over three years compared with TAR-200 for BCG-unresponsive, non–muscle-invasive bladder cancer. Savings per avoided cystectomy were $109,622 in year 1, $151,438 in year 2 and $60,393 in year 3; savings per cystectomy-free month were $9,370, $6,144 and $1,520 in years 1–3, respectively. The study attributed the cost reductions to lower acquisition and administration costs and slightly higher complete response rates (49.6% vs. 45.9%). Investors reacted positively; the stock has returned 272% in the past six months and is trading at $7.74. » Más en de.investing.com


  • ImmunityBio obtains exclusive US rights to Tokio-172 BCG

    ImmunityBio has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokio-172 BCG strain in the U.S. and could become the sole BLA applicant. The decision is based on Phase III SWOG S1602 data showing non-inferiority to TICE BCG (HR 0.82) and an estimated 5-year recurrence-free survival of 64% vs. 58%. Tokio-172 is not yet FDA-approved in the U.S.; ImmunityBio is in discussions with the FDA and research institutions about data use and plans regulatory steps. The company reports strong revenue growth but remains unprofitable, and analysts see further upside potential despite recent share gains. » Más en de.investing.com


  • ImmunityBio posts strong Anktiva sales growth and expands global access

    ImmunityBio reported accelerating commercial traction for Anktiva with Q4 2025 net product revenue up 700% year‑over‑year and unit volumes rising 750%, driven by broadened physician and patient adoption. The company has expanded Anktiva access to 33 countries across four major regulatory jurisdictions and secured an FDA J‑code to improve reimbursement visibility. ImmunityBio is advancing a multi‑layered immunotherapy platform—Anktiva (IL‑15 superagonist), NaNT allogeneic cell therapy, DNA vaccines and Leonardo manufacturing for off‑the‑shelf NK/CAR‑NK products—that management says could scale into an API‑like personalized immune regimen and materially re‑rate the company if execution continues. Continued commercial momentum and regulatory tailwinds underpin a bullish long‑term thesis for IBRX, albeit with execution risk. » Más en finance.yahoo.com


  • ImmunityBio posts 168% y/y product revenue jump as ANKTIVA launch gains traction

    ImmunityBio reported preliminary results for the quarter ending March 31, 2026, with product revenue rising 168% year over year to $44.2 million following the commercial launch of ANKTIVA. The company recorded $113 million net product revenue in 2025 (up 700% from 2024) and ended the quarter with $380.9 million in cash and cash equivalents. ANKTIVA has regulatory approval across five jurisdictions covering 34 countries, and ImmunityBio is focused on scaling U.S. commercialization and global expansion to broaden revenue streams. » Más en finance.yahoo.com

En 2026, ImmunityBio ya ha pagado 0,0574 € en dividendos. El último pago fue en junio.

Datos financieros de la empresa

En el último trimestre, ImmunityBio tuvo unos ingresos de 43,12 M € y un beneficio neto de -162,93 M €
(EUR) septiembre de 2026
YoY
Ingresos 43,12 M 57,83 %
Beneficio bruto 41,98 M 76,37 %
Beneficio neto -162,93 M 184,30 %
EBITDA -131,24 M 330,53 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
6072,58 M €
Número de acciones
1063,83 M
Máximo/mínimo de 52 semanas
11,33 € - 1,78 €
Rentabilidad por dividendo
1,05 %
Dividendos TTM
0,0574 €
Beta
0,13
Ratio P/E
-5,84
Ratio PEG
0,05
Ratio P/B
-5,79
Ratio P/S
36,48

Perfil de la empresa

ImmunityBio, Inc., una empresa de biotecnología en fase clínica, desarrolla terapias y vacunas para tratar cánceres y enfermedades infecciosas. Ofrece plataformas de inmunoterapia y terapia celular, que incluyen proteínas de fusión anticuerpo-citocina, inmunomoduladores sintéticos, tecnologías de vacunas, células asesinas naturales (NK) y sistemas inmunitarios adaptativos (células T). La compañía también desarrolla agentes terapéuticos que se encuentran en ensayos clínicos de fase II o III para el tratamiento de tumores líquidos y sólidos, incluidos los cánceres de vejiga, páncreas y pulmón, así como de patógenos como el SARS-CoV-2 y el VIH. Tiene acuerdos de colaboración con el National Cancer Institute, el National Institute of Deafness and Communication Disorders y Amyris, Inc.; y acuerdos de licencia con CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc. y Viracta Therapeutics, Inc. La empresa fue fundada en 2014 y tiene su sede en San Diego, California.

Nombre
ImmunityBio
CEO
Richard Gerald Adcock
Sede San Diego, ca
Estados Unidos
Sitio web
Sector
Salud
Industria
Biotecnología
Salida a bolsa
28/07/2015
Empleados 688

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
IBRX
Frankfurt
26CA.F
Düsseldorf
26CA.DU
München
26CA.MU
🍪

Parqet  usa cookies. Más información